Rep. Paul A. Gosar

Maddy summaryHR 646, the SHORT Act, clarifies firearm definitions under federal law to exclude antique firearms and certain collector items from the "firearm" category. It removes restrictions on short-barreled rifles and shotguns used lawfully by eliminating specific prohibitions in federal law and preempts state laws imposing taxes or registration requirements on these weapons. The bill also mandates the destruction of federal records related to short-barreled rifles, shotguns, and other weapons defined under the National Firearms Act within 365 days of enactment. This directly affects owners of these specific firearms, particularly collectors and individuals possessing short-barreled weapons legally under federal law. The key mechanisms include revised definitions, federal preemption of state regulations, and record destruction requirements.

Maddy summaryHR 382, the "Pandemic is Over Act," terminates the federal public health emergency declaration for the COVID-19 pandemic. The bill ends the emergency status declared on January 31, 2020, effective upon the bill's enactment. This action directly ends the federal authority tied to the emergency, including related public health measures and funding mechanisms under the Public Health Service Act.

Maddy summaryThe Restoring Military Focus Act (HR 678) repeals the Chief Diversity Officer position in the Department of Defense and prohibits the creation of similar roles. It specifically eliminates two existing positions: the Chief Diversity Officer (under pre-2021 Title 10, U.S. Code) and the Senior Advisor for Diversity and Inclusion (under the 2021 National Defense Authorization Act). The bill bans federal funding for any new position that matches or closely resembles these roles. This directly affects the Department of Defense's organizational structure by removing diversity-focused leadership roles and preventing their replacement.

This resolution expresses support for the Supreme Court's holding in Dobbs v. Jackson Women's Health Organization (that there is no constitutional right to abortion). The resolution also applauds the courage of the Justices for standing by their allegiance to the Constitution and the legitimacy of the Supreme Court, and it expresses a commitment to supporting policies that continue to protect all life.

Prohibiting Abortion Industry's Lucrative Loopholes Act This bill expands the prohibition on the sale or purchase of human fetal tissue in interstate commerce to include any payments associated with the transportation, implantation, processing, preservation, quality control, or storage of such tissue.

Maddy summaryThis bill would prohibit the FDA from approving new abortion medications or investigational uses of existing ones. It would restrict currently approved abortion drugs to in-person administration only in clinics, hospitals, or medical offices by certified providers who can handle complications like ectopic pregnancy or severe bleeding. The law requires detailed adverse event reporting (excluding patient identifiers) to the FDA by both manufacturers and prescribers, and mandates provider certification covering pregnancy assessment, surgical intervention capabilities, and patient safety documentation. These provisions apply directly to healthcare providers, patients seeking medication abortions, and manufacturers of abortion drugs.

Protecting Life and Taxpayers Act of 2023 This bill requires federally funded entities to certify that they will not, subject to certain exceptions, perform abortions or provide funding to other entities that perform abortions. The bill provides exceptions for abortions (1) in cases of rape or incest; or (2) when the life of the woman is in danger due to a physical disorder, injury, or illness.

This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.

Maddy summaryThis bill prohibits federal funding to Planned Parenthood Federation of America and its affiliates for one year unless they certify they won't perform or fund abortions (with exceptions for rape/incest or life-threatening conditions). It redirects $235 million in existing funding to community health centers for women's health services like contraception, cancer screenings, and prenatal care. The bill explicitly states that redirected funds will continue to support all women's health services previously provided by Planned Parenthood. It also requires repayment of funds if Planned Parenthood violates the certification, and clarifies that overall federal funding for women's health services remains unchanged.

Protecting Life from Chemical Abortions Act This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits the FDA from (1) exercising any enforcement discretion with respect to program requirements, or (2) reducing program protections until every state submits certain data regarding abortions to the Centers for Disease Control and Prevention. The bill also generally prohibits the declaration of a public health emergency with respect to abortions.